Glial Cell Transplantation Shows Promise in Slowing Huntington's Disease in Adult Mice

Recent research has demonstrated that transplanting healthy human glial progenitor cells into the brains of adult mice affected by Huntington's disease can significantly slow disease progression and extend lifespan. Published in Cell Reports, the study reveals that this approach not only mitigates motor and cognitive symptoms but also restores vital neuronal functions. The research focused on R6/2 mice, a common model for Huntington's, which were injected with early-stage glial cells before severe symptoms had developed. Subsequent analysis showed that many genes responsible for maintaining synaptic function in neurons were reactivated after glial transplantation. Additionally, the structural integrity of neurons, including dendritic branching and spine density, improved substantially. Experts note that glial cells—once regarded as mere support for neurons—are now recognized as key players in brain health and disease. Dr. Steve Goldman, lead author of the study, emphasized that restoring healthy glial support even after symptoms emerge could reset neuronal gene expression, stabilize synapses, and slow disease progression. This research signifies a shift in treating Huntington's from neuron-centric strategies toward supporting brain support cells, opening new avenues for adult intervention. The findings suggest that glial replacement could become part of comprehensive treatment regimens, especially when combined with gene-targeting therapies. While further studies are needed to optimize delivery methods and dosing, this breakthrough underscores the potential for cell-based therapies to alter the course of neurodegenerative diseases.